ArticleWorld journal of surgical oncology2025
Reinterpretation of the clinical and biological behaviors of papillary thyroid carcinoma subtypes within the 2022 WHO classification: a cross-sectional study of 768 cases.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- UTMD Suppresses CSF-1 to Drive Macrophage-Mediated Ferroptosis in Papillary Thyroid Carcinoma.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLimited comprehensive evaluations have been conducted to date regarding the clinical behavior of papillary thyroid carcinoma (PTC) subtypes based on the 2022 World Health Organization (WHO) classification of thyroid neoplasms.
methodsA total of 768 patients who underwent surgical treatment for PTC were retrospectively categorized into 12 subtypes according to the 2022 WHO classification system. Clinical and pathological variables including incidence rate, age at onset, sex, anatomical location of lesions, lesion size, presence of lymph node metastasis, capsular invasion, tumor microenvironmental features, familial predisposition, and gene mutations were comparatively analyzed across these subtypes.
resultsAmong the 12 identified subtypes, the diffuse sclerosing subtype (DSS) demonstrated the highest incidence, followed by the encapsulated subtype (ES) and the subtype with fibromatosis/fasciitis-like stroma (WF/FLS). The spindle cell subtype (SCS) exhibited the lowest incidence. An annual increase in the incidence of WF/FLS subtypes was observed. Multifocal lesion occurrence was significantly more frequent in individuals with the DSS subtype compared to the overall PTC cohort (p < 0.05). Lymph node metastasis rates were notably elevated in the hobnail subtype (HS), tall cell subtype (TCS), DSS, and Warthin-like subtype (WLS). The prevalence of Hashimoto's thyroiditis was significantly lower in the ES subtype (p < 0.05) and significantly higher in the WLS subtype (p < 0.001), relative to the broader PTC population. Subtypes including Solid subtype (SS), WF/FLS, HS, and WLS demonstrated higher frequencies of familial tumor history. Although gene mutation rates were elevated across all subtypes, no statistically significant differences were identified among them.
conclusionPapillary thyroid carcinoma subtypes defined by the 2022 WHO classification exhibit distinct demographic, pathological, and molecular profiles. Subtypes such as hobnail, tall cell, diffuse sclerosing, and Warthin-like show aggressive features, while encapsulated, infiltrative follicular, and oncocytic types follow indolent courses.The high familial rate and increasing trend of the WF/FLS subtype provide novel insight into its possible genetic and microenvironmental influences. Recognizing these subtype-based differences may refine surgical decision-making, risk stratification, and postoperative surveillance strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.